43(B)log

NOVEMBER 19, 2021

This designation did not indicate that Valtoco was safe or effective for public use but, instead, operated to qualify Neurelis for various development incentives, like tax credits and potential exclusivity for seven years if the FDA ultimately approved Valtoco.”

Designs 56

Designs Design Patent Prosecution Art 56

Patently-O

JANUARY 21, 2023

Identify any specific sources of prior art not currently available through the Patents End-to-End Search system that you believe examiners should be searching. Terminal disclaimers, allowed under 37 CFR 1.321(d) , allow applicants to receive patents that are obvious variations of each other as long as the expiration dates match.

Patent 93

Patent Invention Patent Prosecution Art 93

LexBlog IP

OCTOBER 25, 2022

Identify any specific sources of prior art not currently available through the Patents End-to-End Search system that you believe examiners should be searching. How would eliminating terminal disclaimers, thus prohibiting patents that are obvious variations of each other, affect patent prosecution strategies and patent quality overall?

Invention 52

Invention Patent Prosecution Art Patent 52